NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT05655949 2025-03-10
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06274879 2025-01-09
Ablatio
Insel Gruppe AG, University Hospital Bern
Phase 2 Not yet recruiting
NCT04298008 2024-04-19
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Recruiting
NCT04298021 2024-04-19
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Active not recruiting
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed